Skip to Content

Starpharma Holdings Ltd ADR SPHRY

Morningstar Rating
$0.86 +0.01 (1.18%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

SPHRY is trading at a 53% discount.
Price
$0.86
Fair Value
$9.64
Uncertainty
Extreme
1-Star Price
$33.00
5-Star Price
$8.47
Economic Moat
Wqnc
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SPHRY is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.85
Day Range
$0.860.86
52-Week Range
$0.773.45
Bid/Ask
$0.82 / $1.00
Market Cap
$35.44 Mil
Volume/Avg
101 / 3,453

Key Statistics

Price/Earnings (Normalized)
Price/Sales
5.87
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating and VIRALEZE an antiviral nasal spray.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
32

Comparables

Valuation

Metric
SPHRY
SCLX
300142
Price/Earnings (Normalized)
41.67
Price/Book Value
1.512.57
Price/Sales
5.873.795.82
Price/Cash Flow
18.03
Price/Earnings
SPHRY
SCLX
300142

Financial Strength

Metric
SPHRY
SCLX
300142
Quick Ratio
5.220.15
Current Ratio
5.600.19
Interest Coverage
−106.04
Quick Ratio
SPHRY
SCLX
300142

Profitability

Metric
SPHRY
SCLX
300142
Return on Assets (Normalized)
−16.39%−106.47%
Return on Equity (Normalized)
−22.84%
Return on Invested Capital (Normalized)
−23.09%−1,960.39%
Return on Assets
SPHRY
SCLX
300142
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRYlnfcbnzsPykbw$564.6 Bil
REGN
Regeneron Pharmaceuticals IncTkjdddqmqLmffdm$102.8 Bil
VRTX
Vertex Pharmaceuticals IncFcgylyqgJsbtpq$102.5 Bil
MRNA
Moderna IncHsxgyrssFvgtr$41.0 Bil
ARGX
argenx SE ADRCrbyrptLlnzx$22.8 Bil
BNTX
BioNTech SE ADRJblnbqwkbPbq$21.7 Bil
ALNY
Alnylam Pharmaceuticals IncYnrhwjptRtbmk$18.8 Bil
BMRN
Biomarin Pharmaceutical IncGfbppcjsfMcjsnp$17.4 Bil
RPRX
Royalty Pharma PLC Class ATbxbvlvkmSlvzzdp$12.6 Bil
INCY
Incyte CorpSwxptgrqMtqvfb$12.1 Bil

Sponsor Center